Filed with ASX · · 4 pages · English
Algorae Pharmaceuticals Limited has announced a partnership with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre for a third AI-driven drug synergy screening program. This initiative is supported by a Therapeutic Innovation Australia Pipeline Accelerator voucher awarded to the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited [ABN: 14 104 028 042] Level 23, Rialto South Tower, 525 Collins St, Melbourne VIC 3000 ASX ANNOUNCEMENT ASX: 1AI |16 October 2026 Algorae Pharmaceuticals Partners with Peter MacCallum Cancer Centre for Third AI-driven Drug Synergy Screening Program Highlights ...
Algorae Pharmaceuticals Limited on 6ix
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals